miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2

Experimental Hematology ◽

10.1016/j.exphem.2018.09.001 ◽

2018 ◽

Vol 68 ◽

pp. 80-88.e2 ◽

Author(s):

Bin Pan ◽

Jing Yang ◽

Xiangmin Wang ◽

Kailin Xu ◽

Takayuki Ikezoe

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Leukemia Cells ◽

Chronic Myelogenous Leukemia Cells

Download Full-text

FTY720 induces apoptosis of chronic myelogenous leukemia cells via dual activation of BIM and BID and overcomes various types of resistance to tyrosine kinase inhibitors

APOPTOSIS ◽

10.1007/s10495-013-0882-y ◽

2013 ◽

Vol 18 (11) ◽

pp. 1437-1446 ◽

Author(s):

Miki Kiyota ◽

Junya Kuroda ◽

Mio Yamamoto-Sugitani ◽

Yuji Shimura ◽

Ryuko Nakayama ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Leukemia Cells ◽

Chronic Myelogenous Leukemia Cells ◽

Dual Activation

Download Full-text

Abstract 5892: miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2

10.1158/1538-7445.am2018-5892 ◽

2018 ◽

Author(s):

Bin Pan ◽

Xiangmin Wang ◽

Kailin Xu ◽

Takayuki Ikezoe

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Leukemia Cells ◽

Chronic Myelogenous Leukemia Cells

Download Full-text

Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells

Cancer Science ◽

10.1111/cas.13442 ◽

2017 ◽

Vol 109 (1) ◽

pp. 121-131 ◽

Author(s):

Takuya Hirao ◽

Masashi Yamaguchi ◽

Megumi Kikuya ◽

Hiroji Chibana ◽

Kousei Ito ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Intracellular Signaling ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Leukemia Cells ◽

Anti Cancer ◽

Chronic Myelogenous Leukemia Cells

Download Full-text

Extranodal marginal zone lymphoma arising in a patient with chronic myelogenous leukemia on long-term tyrosine kinase inhibitors

Leukemia & Lymphoma ◽

10.3109/10428194.2013.811581 ◽

2013 ◽

Vol 55 (3) ◽

pp. 715-717 ◽

Author(s):

Xiangdong Xu ◽

Anjum Hassan

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Marginal Zone ◽

Marginal Zone Lymphoma ◽

Myelogenous Leukemia ◽

Extranodal Marginal Zone Lymphoma

Download Full-text

Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees

Leukemia & Lymphoma ◽

10.1080/10428194.2020.1855340 ◽

2020 ◽

pp. 1-15

Author(s):

Eric J. Chow ◽

David R. Doody ◽

Jennifer J. Wilkes ◽

Laura K. Becker ◽

Shasank Chennupati ◽

...

Keyword(s):

Adverse Events ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Health Plan ◽

Kinase Inhibitors ◽

Myelogenous Leukemia

Download Full-text

Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor

Oncogene ◽

10.1038/s41388-018-0157-8 ◽

2018 ◽

Vol 37 (21) ◽

pp. 2837-2849 ◽

Author(s):

Yu Zhu ◽

Luo Lu ◽

Chun Qiao ◽

Yi Shan ◽

Huapeng Li ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitor ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitor ◽

Myelogenous Leukemia ◽

Leukemia Cells ◽

Chronic Myelogenous Leukemia Cells

Download Full-text

Clinical and prognostic significance of 3q26 rearrangements and other chromosome 3 abnormalities in chronic myelogenous leukemia in era of tyrosine kinase inhibitors

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2015.07.067 ◽

2015 ◽

Vol 15 ◽

pp. S32-S33

Author(s):

Wei Wang ◽

Jorge Cortes ◽

Pei Lin ◽

Michael Beaty ◽

Di Ai ◽

...

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Prognostic Significance ◽

Myelogenous Leukemia ◽

Download Full-text

Extending the duration of response in chronic myelogenous leukemia: targeted therapy with sequential tyrosine kinase inhibitors

Oncology Reviews ◽

10.1007/s12156-009-0004-9 ◽

2009 ◽

Vol 3 (1) ◽

pp. 59-70

Author(s):

Michael G. Martin ◽

John F. DiPersio ◽

Geoffrey L. Uy

Keyword(s):

Targeted Therapy ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Duration Of Response

Download Full-text

Blast Phase in Chronic Myelogenous Leukemia Is Skewed Toward Unusual Blast Types in Patients Treated With Tyrosine Kinase Inhibitors

American Journal of Clinical Pathology ◽

10.1309/ajcpwex5yy4phscn ◽

2015 ◽

Vol 143 (1) ◽

pp. 105-119 ◽

Author(s):

Yang Shi ◽

Andrew J. Rand ◽

Jennifer H. Crow ◽

Joseph O. Moore ◽

Anand S. Lagoo

Keyword(s):

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Myelogenous Leukemia ◽

Download Full-text

Unfavorable outcome of chronic myelogenous leukemia in adolescent and young adults treated with tyrosine kinase inhibitors

International Journal of Hematology ◽

10.1007/s12185-015-1840-y ◽

2015 ◽

Vol 102 (3) ◽

pp. 342-348 ◽

Author(s):

Masatoshi Sakurai ◽

Takehiko Mori ◽

Daiki Karigane ◽

Keiichi Tozawa ◽

Eri Matsuki ◽

...

Keyword(s):

Young Adults ◽

Tyrosine Kinase ◽

Tyrosine Kinase Inhibitors ◽

Chronic Myelogenous Leukemia ◽

Kinase Inhibitors ◽

Unfavorable Outcome ◽

Myelogenous Leukemia ◽

Adolescent And Young Adults

Download Full-text